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Autophagy is an intracellular degradation process responsible for the clearance of most long-lived pro-
teins and organelles. Cytoplasmic components are enclosed by double-membrane autophagosomes,
which subsequently fuse with lysosomes for degradation. Autophagy dysfunction may contribute toutophagy
lzheimer disease
eurodegeneration
untington disease
the pathology of various neurodegenerative disorders, which manifest abnormal protein accumulation.
As autophagy induction enhances the clearance of aggregate-prone intracytoplasmic proteins that cause
neurodegeneration (like mutant huntingtin, tau and ataxin 3) and confers cytoprotective roles in cell
and animal models, upregulating autophagy may be a tractable therapeutic strategy for diseases caused
by such proteins. Here, we will review the molecular machinery of autophagy and its role in neurode-
generative diseases. Drugs and associated signalling pathways that may be targeted for pharmacological
induction of autophagy will also be discussed.
© 2010 Elsevier Ltd. 
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. The basics of autophagy
Autophagy is an intracellular catabolic system in which
ytoplasmic components are delivered into lysosomes for
egradation. Three different autophagic pathways are known:
1) macroautophagy, (2) microautophagy, and (3) chaperone-
ediated autophagy (CMA). In macroautophagy, a double-
embraned structure (called a phagophore) elongates engulﬁng
portion of cytoplasm, and then fuses to form a vesicle called
n autophagosome. Autophagosomes fusewith lysosomes, thereby
orming autolysosomes, where the cytosolic contents are degraded
y lysosomal hydrolases. In microautophagy, a portion of cyto-
lasm is directly engulfed into lysosomes by invagination of the
ysosomal membrane. CMA involves the selective transport of
ytosolic proteins that contain a pentapeptide motif related to
FERQ across the lysosomal membrane via the chaperone hsc70
nd the lysosomal membrane receptor LAMP-2A.
In this review, we will focus on mammalian macroautophagy,
ereafter referred to as autophagy, and its roles in neurode-
eneration. Basal autophagy plays an important role in cellular
omeostasis, through the degradation of long-lived proteins, pro-
ein aggregates and organelles. In addition, autophagy can also be
nducedasa cellular reaction tovariousphysiological andpatholog-
cal situations, such as nutrient starvation, or pathogen infection.
hus, dysfunction in autophagy has been implicated in the patho-
enesis of various diseases, like cancer, infectious diseases and
eurodegenerative disorders [1].
. Autophagy machinery
Our understanding of the molecular machinery of autophagy
tartedwith the identiﬁcationof theautophagy-related (ATG) genes
n Saccharomyces cerevisiae. To date, more than 30 different ATG
enes have been identiﬁed in yeast [2], and many of them have
ammalian orthologues.
.1. Initiation of autophagosome formation
Autophagosome formation occurs at the phagophore-
ssembly-site(s) (PAS) [3]. The activity of Vps34, a class
II phosphatidylinositol-3-kinase (PI3K), is necessary for
he formation of new autophagosomes. Vps34 generates
hosphatidylinositol-3-phosphate (PI3-P) at the PAS, which
llows the recruitment of other Atg proteins. Vps34 is part of the
utophagy-regulating macromolecular complex (PI3K complex),
hich contains Beclin 1/Atg6, Atg14/barkor and p150/Vps15,
mong other proteins [4]. The activity of Vps34 is enhanced by its
inding to Beclin 1. Positive regulators of Beclin 1 function and
utophagy include AMBRA1, UVRAG and Bif-1, whereas its nega-
ive regulators include the anti-apoptotic proteins Bcl-2 and Bcl-XL
5]. The other protein complex involved in this stage of autophago-
ome formation is the ULK1/Atg1–Atg13–FIP200/Atg17–Atg101
omplex [6]. This complex plays an important role in both the
ecruitment of Atg proteins and the subsequent autophagosome
ynthesis.
.2. Elongation
Twoubiquitin-likeconjugationsystemsare involved in theelon-
ation and expansion of the phagophore membrane. In the ﬁrst
onjugation event, Atg12 is conjugated to Atg5 in a reaction that
equires Atg7 (E1-like) and Atg10 (E2-like) [7]. The Atg12–Atg5
onjugate interacts non-covalently with Atg16L, which oligomer-
zes to form an 800-kDa complex [8], which is necessary for
utophagosome formation.evelopmental Biology 21 (2010) 691–698
The second ubiquitination-like reaction involves the con-
jugation of microtubule-associated protein 1 light chain 3
(MAP1-LC3/LC3/Atg8) to the lipid phosphatidylethanolamine (PE).
LC3 is cleaved at its C terminus by Atg4 to form the cytosolic LC3-I,
which is conjugated with PE through the action of Atg7 (E1-like)
and Atg3 (E2-like) to generate LC3-II [9]. LC3-II is the most widely
usedmarker to studyautophagy, as it is theonlyknownprotein that
speciﬁcally associates with autophagosomes and not with other
vesicular structures. LC3-II is bound to both sides of themembrane,
and it remains membrane bound even after fusion with lysosomes,
after which LC3-II on the cytosolic face of autophagosomes can be
recycled (to LC3-I) by Atg4 [10], while the LC3-II on the inner face
of the membrane is degraded.
2.3. Maturation and fusion
Mammalian autophagosomes form randomly in the cytoplasm.
They are then trafﬁcked alongmicrotubules in a dynein-dependent
manner to lysosomes,which are clustered around themicrotubule-
organising center (MTOC) located near the nucleus [11]. The details
of the autophagosome–lysosome fusion in mammalian autophagy
are still unclear, although it is thought that the fusion step involves
proteins such as ESCRT, SNAREs, Rab7, UVRAG, LAMP-2 and the
class C Vps proteins [12,13].
3. Signalling pathways regulating mammalian autophagy
3.1. mTOR-dependent pathway
The mammalian target of rapamycin (mTOR) kinase is a master
negative regulator of autophagy [14] (Fig. 1). mTOR is a cen-
tral sensor of energy status, growth factors and nutrient signals,
and can be inhibited by drugs such as rapamycin [15]. Under
nutrient-rich conditions, mTOR suppresses autophagy through
direct interactionwith theULK1–Atg13–FIP200complexandmedi-
ates phosphorylation-dependent inhibition of the kinase activity
of Atg13 and ULK1. Under starvation conditions or rapamycin
treatment, mTOR-mediated phosphorylation of Atg13 and ULK1 is
inhibited. This leads to dephosphorylation-dependent activation of
ULK1 and ULK1-mediated phosphorylations of Atg13, FIP200, and
ULK1 itself, which trigger autophagy [6].
A major signalling cascade regulating mTOR activity is the PI3K
pathway. The binding of growth factors or insulin to cell surface
receptors activates the class 1a PI3K. Activated PI3K catalyzes the
productionof phosphatidylinositol-3,4,5-triphosphate (PIP3) at the
plasma membrane, which increases the membrane recruitment of
Akt/PKB and its activator PDK1, leading to the activation of Akt.
The phosphorylation-dependent Akt activation results in the phos-
phorylation of a host of other proteins, including the tuberous
sclerosis complex 1/2 (TSC1/TSC2). The TSC1/TSC2 complex inte-
grates upstream signals from various kinases, including AKT and
ERK1/2 [16]. Phosphorylation of TSC2 by these kinases leads to
the disruption of the heterodimer with TSC1, resulting in loss of
TSC1/TSC2 activity. Since TSC1/TSC2 acts as the GTPase-activating
protein (GAP) for the Ras-family GTP binding protein, Rheb, which
directly binds and activates mTOR [17], loss of TSC1/TSC2 activity
results in mTOR activation.
mTORcan also act as a sensor of changes in cellular energy states
viaAMPK[18].AMPK, activatedwhencells areenergy-depletedas it
senses changes in intracellular AMP/ATP ratios, directly phospho-
rylates TSC2, thereby providing the priming phosphorylation for
subsequent phosphorylation of TSC2 by glycogen synthase kinase
3 (GSK3) to inhibit mTOR signalling [19].
The p53 tumor suppressor, encoded by a commonly mutated
gene in human cancers, can positively and negatively regulate
M. García-Arencibia et al. / Seminars in Cell & Developmental Biology 21 (2010) 691–698 693
g at di
a
s
a
t
i
a
i
B
a
a
m
a
E
s
3
u
t
i
i
l
i
c
n
s
p
s
i
m
v
t
w
c
b
T
aFig. 1. mTOR-dependent pathway, with drugs actin
utophagy depending on its localization. Oncogenic or genotoxic
tress stabilizes and activates nuclear p53. This can stimulate
utophagy by activating AMPKor by upregulating phosphatase and
ensin homologue (PTEN, a PIP3 3′ phosphatase) and TSC1 which
nhibits mTOR. Cytoplasmic p53, however, inhibits autophagy [20].
Recently, further insights have been provided into the mech-
nisms behind starvation-induced autophagy. Autophagy can be
nhibited by the binding of the apoptosis-related proteins Bcl-2 or
cl-XL to Beclin 1. Starvation induces JunN-terminal kinase 1 (Jnk1)
ctivity, which phosphorylates Bcl-2, thereby disrupting the inter-
ction between Beclin 1 and Bcl-2 to induce autophagy [21]. This
echanism might also account for the upregulation of autophagy
fter proteasome inhibition or ER stress, as one study shows that
R-stress-induced autophagy is Jnk1-dependent and that protea-
ome inhibition can induce ER stress [22].
.2. mTOR-independent pathway
The ﬁrst evidence for the existence of mTOR-independent reg-
lation of mammalian autophagy comes from studies showing
hat autophagy is negatively regulated by intracellular inositol and
nositol 1,4,5-trisphosphate (IP3) leves [23] (Fig. 2). Inhibition of
nositol monophosphatase (IMPase) reduces free inositol and IP3
evels, which leads to an upregulation of autophagy. Autophagy is
nhibited when intracellular cAMP levels are increased by adenylyl
yclase (AC). cAMP inhibits autophagy via Epac, which is a gua-
ine nucleotide exchange factor. Epac then activates Rap2B, that
ubsequently activates phospholipase C (PLC), resulting in the
roduction of IP3, which mediates the release of Ca2+ from ER
tores. Increased intracytosolic Ca2+ blocks autophagy by activat-
ng calpains (a family of Ca2+-dependent cysteine proteases),which
ediate their effects on autophagy through Gs, which is acti-
ated after calpain cleavage. This, in turn, increases AC activity
o increase cAMP levels. This creates a potential cyclic pathway
here calpain regulates autophagy throughGs that signals via the
AMP–Epac–PLC–IP3 pathway, which modulates calpain activity
y inﬂuencing Ca2+ levels [24].
Autophagy is also modulated by reactive oxygen species (ROS).
he generally deleterious effect of ROS on intracellular structures
nd their association with disease means they have traditionallystinct stages in this pathway enhancing autophagy.
been considered as harmful. However, ROS also have physiologi-
cal roles in the cell, notably in signalling [25]. Starvation (a potent
inducer of autophagy) increases levels of ROS in a PI3K-dependent
manner, and treatment with antioxidants ameliorates the ability
of starvation to induce autophagy [26]. One way in which ROS may
be acting to regulate autophagy is by the modulation of the action
of Atg4 on Atg8/LC3. The Atg4-mediated delipidation of LC3-II on
the cytosolic surface of autolysosomes allows it to be recycled. Atg4
is inactive and unable to cleave Atg8 from membranes when in its
oxidized state [27]. It is therefore possible that under oxidative con-
ditions Atg4 is oxidized and inactive, which allows Atg8 to lipidate
and thus initiates autophagy, while reduced Atg4 is active favoring
Atg8 delipidation.
4. Neurological diseases caused by mutations that
compromise autophagy
One of the common pathological features of most adult-onset
human neurodegenerative diseases is the formation of intracyto-
plasmic aggregates within neurons and other cell types. This is
seen in Alzheimer disease and in tauopathies (where tau accumu-
lates in the cytoplasm), in Parkinson disease (where -synuclein
is the major component of the aggregates), and in polyglutamine
expansion diseases like Huntington disease, where the mutant
protein is the primary constituent of the aggregates. A com-
mon theme emerging in these studies is the role of autophagy
in degrading disease-related, aggregate-prone, mutant, intracyto-
plasmic proteins such as tau, huntingtin and mutant -synuclein
[28]. Extensive data suggest that such aggregate-prone proteins
mediate toxicity primarily via gain-of-function mechanisms asso-
ciated with their propensity to aggregate.
The concept of autophagy failure as a mechanism predispos-
ing to cell death is relevant to pathogenesis in a range of diseases.
Autophagy is necessary for the clearance of aggregate-prone pro-
teins that are toxic, especially for post-mitotic cells like neurons
[29]. Neuronal autophagy was initially believed to be relatively
inactive, however, recent genetic studies using mice have high-
lighted the importance of constitutive autophagy in nondividing
cells such as neurons [30,31].Mice deﬁcient for Atg5 or Atg7 specif-
ically in neural cells develop progressive deﬁcits in motor function
694 M. García-Arencibia et al. / Seminars in Cell & Developmental Biology 21 (2010) 691–698
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hat are accompanied by an accumulation of cytoplasmic inclu-
ion bodies in neurons. These results demonstrate that constitutive
utophagy is relatively active in neurons and that clearance of dif-
use cytosolic proteins through basal autophagy is important for
reventing the accumulation of abnormal proteins which may dis-
upt neural function, even in the absence of disease-associated
utations [30,31]. The compromise of autophagy as a possible con-
ributor to different neurological diseases will be reviewed below
ith some examples.
.1. Dynein
Eukaryotic cells transport molecules, complexes and organelles
round the cell by means of energy-dependent motor proteins. The
ain motor responsible for movement of cargos to the minus end
f microtubules is cytoplasmic dynein, which moves cargo cen-
ripetally towards the MTOC near the nucleus. Plus-end-directed
inesins move cargo in the opposite direction, centrifugally, out-
ards into the cytoplasm and the plus end of microtubules [32].
In contrast tomost eukaryotic cells, neurons possess long highly
ranched processes, which make them exceptionally sensitive
o defects in dynein function. Dynein and dynactin have multi-
le cellular house-keeping roles which include retrograde axonal
ransport, neurotrophic factor signalling, neuroﬁlament transport,
RNA localization, neuronal migration, and protein recycling and
egradation [32,33]. Disruption of dynein or dynactin is therefore
xpected to severely compromise the function and health of neu-
ons.Mutations in the core of thismotor – the dynein heavy chain –
ontribute to the pathogenesis of multiple neurodegenerative dis-
ases [33,34] aswell as producemotor neurondegeneration similar
o what is seen in amyotrophic lateral sclerosis (ALS) [35]. Stud-
es both in ALS patients and in transgenic animals have revealeding at various places in this pathway that induce autophagy.
decreased axonal transport in both anterograde and retrograde
directions [36].
One key role for dyneins is to mediate the movement of
autophagosomes along microtubules towards lysosomes clustered
at the MTOC. This brings autophagosomes close to lysosomes, a
prerequisite for subsequent fusion. The equilibrium that exists
between autophagosome formation and clearance by lysosomes,
termed autophagic ﬂux, is microtubule-dependent, as the admin-
istration of microtubule-depolymerizing compounds such as
vinblastine [37] or nocodazole [38] disrupts microtubule assembly
and autophagosome transport to lysosomes, resulting in the rapid
accumulationof autophagosomes,whilepreventing the turnoverof
LC3-II associated within these compartments. Under these condi-
tions, autophagosome maturation and autophagosome–lysosome
fusion aredecreased, as autophagosomes areunable to shuttle from
the cell periphery to the MTOC [11]. Indeed a similar increase in
autophagosome number and LC3-II levels along with decreased
autophagic ﬂux can be observed in dynein-defective transgenic
cells and mice [34].
4.2. Lysosomal storage diseases
Lysosomal storage diseases (LSDs) are a group of over 60
genetic conditions [39], most of which are caused by deﬁciency
of lysosomal hydrolases leading to the accumulation of the cor-
responding substrate inside lysosomes. This, in turn, leads to a
progressive accumulation of poly-ubiquitinated protein aggregates
and of dysfunctional mitochondria [40]. A common cellular patho-
logical feature in these diseases and their animal models is the
manifestation of aberrant autophagic activity as evidenced by the
accumulation of autophagosomes and increased levels of LC3-II,
accompanied by neurodegeneration [41]. Deletion of genes encod-
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ng lysosomal enzymes such as cathepsins B and L in mouse brain
42], or pharmacological inhibition of lysosomal cysteine proteases
43] yield similar neurodegenerative states.
The ﬁrst evidence for an involvement of autophagy in lysoso-
al storage diseases was obtained in a mouse model of Danon
isease [44], in which the accumulation of autophagic vacuoles
as observed in several tissues. Similarly, autophagosome accu-
ulationwasobserved inneurons frommurinemodels of neuronal
eroid-lipofuscinoses (NCLs)[45], as well as Pompe disease [46] in
hich a signiﬁcant disturbance of the autophagic pathway was
emonstrated.
A recent study [40,47] identiﬁed an inhibition block
f autophagy in multiple sulfatase deﬁciency (MSD) and
ucopolysaccharidosis type IIIA. MSD, an aggressive neurode-
enerative disorder that results in death, is caused by mutations
n sulfatase modifying factor (SUMF), the gene that encodes the
ormylglycine-generating enzyme (FGE) [48,49], required for
osttranslational activation of sulfatases. Without this modiﬁca-
ion, sulfatase activity is impaired and the enzymes are therefore
nable to degrade lysosomal contents. Analysis of the cell lines
erived from MSD mice and their wild-type littermates show a
ecrease in the colocalization of the lysosomal marker, LAMP-1,
nd LC3 in MSD mouse embryonic ﬁbroblasts (MEFs) [40,47], and
he accumulation of autophagosomes resulting from impaired
usion of autophagosomes with lysosomes. This leads to a general
mpairment of autophagic protein degradation in these diseases.
.3. The ESCRT complex
One of the important pathways involved in dendritic mainte-
ance is the endosomal–lysosomal pathway, which plays a major
ole in the homeostatic regulation of transmembrane proteins.
ndocytic cargos in early endosomes are either returned to the cell
urface or trafﬁcked to lysosomes for degradation. A critical step in
egradation is the formation of multivesicular bodies (MVBs)—late
ndosomal compartments formed through the inward invagination
ndbudding of vesicles into the lumenof endosomes. Theﬁdelity of
hisprocess ismaintainedby the sequential interactionof four com-
lexes ESCRT-0, -I, -II and -III plus several accessory components
ermed the endosomal sorting complexes required for transport
ESCRT) [12]. The speciﬁc interactions between these complexes
re necessary for the formation of the MVB and proper progression
f endosomal–lysosomal fusion.
In addition to roles in viral budding, cytokinesis, cancer and bac-
erial infection [50], the ESCRT complex is strongly implicated in
eurodegenerative diseases [51]. The most direct evidence comes
rom the identiﬁcation of individuals with missense mutations
n the ESCRT-III subunit Vps2B who develop neurodegenerative
iseases, like ALS and frontotemporal dementia (FTD), both charac-
erized by progressive neuronal accumulation of ubiquitin-positive
rotein aggregates. Depletion of ESCRT-III or overexpression of
ps2b mutant proteins in cortical neurons presents with a similar
henotype [52].
Genetic and ultrastructural analysis in Drosophila melanogaster
eveal that ESCRT-I, -II and -III, as well as their regulatory ATPase
ps4, are all essential for normal autophagy function [51,53].
eﬁcient ESCRT function results in elevatednumbers of autophago-
omes due to impaired autolysosome formation, and this is
ssociated with the formation of large protein aggregates that
ontain the autophagy substrate p62 [12,54]. While some protein
ggregates are seen within autophagosomes, large aggregates that
re not membrane bound are also a prominent feature of this deﬁ-
iency. The observation that autophagosomes contain decreased
AMP-1 in ESCRT-III-deﬁcient neurons and in Drosophila models
eﬁcient for ESCRT-I and ESCRT-II, suggests that the normal ESCRT
unction is required for autophagosome–lysosome fusion [12,53].evelopmental Biology 21 (2010) 691–698 695
4.4. Alzheimer disease
Alzheimer disease (AD) is a neurodegenerative disorder charac-
terized by progressive dementia and brain morphological changes
suchas atrophy, senileplaqueswithﬁbrillogenicbeta amyloid (A),
and intraneuronal neuroﬁbrillary tangles (NFT) with hyperphos-
phorylated tau. In AD brain, A accumulates within the large pool
of autophagic vacuoles in swollen dystrophic neurites, suggesting
that the autophagy system is involved in ADpathogenesis [55]. One
probable contributor to autophagy deﬁciency in AD appears to be
Beclin 1, whose expression is strongly reduced in the brains of AD
patients to levels thatwouldbepredicted to impair autophagosome
synthesis [56]. Genetic manipulations that decrease Beclin 1 levels
in AD transgenic mice reduce neuronal autophagy, disrupt lyso-
somes, promote intracellular and extracellular A accumulation,
and enhance neurodegeneration. Conversely, increasing Beclin 1
expression results in diminished amyloid pathology in these AD
transgenic mice [57]. These data raise the possibility that upreg-
ulation of autophagy may be beneﬁcial in AD by decreasing the
levels of A that characterize its pathology. It is interesting that
the prediction of these Beclin 1 data would be decreased numbers
of autophagosomes in AD brains, yet the converse is seen in many
cases with established disease [55]. One possibility to reconcile
this apparent discrepancy may be that autophagosome synthesis
is partially defective very early on, possibly before overt pathology
appears, and that the Beclin 1 deﬁciency may play an important
role in the genesis of disease. Then, as disease progresses, there
may be additional events that impair autophagosome clearance,
leading to a situation where, despite reduced autophagosome syn-
thesis, there is abuildupof autophagosomesdue toa “trafﬁc jam” in
their removal processes. This may compound the autophagy prob-
lemand further reduce autophagic ﬂux. Furthermore, the abnormal
pool of slowly turned over autophagic vesicles may additionally
impact on AD pathology by serving as a site for beta-amyloid gen-
eration [55].
4.5. Parkinson disease
In Parkinson disease (PD), death of dopaminergic neurons in the
substantia nigra is associated with accumulation of -synuclein
within inclusions called Lewy bodies. Autophagy has been pre-
viously associated with PD through the protein PINK1, which is
mutated in autosomal recessive forms of PD [58]. Full-length PINK1
interacts with Beclin 1 and this appears to act as a positive medi-
ator of autophagy. A mutant form of PINK1 (W437X) does not
interact normally and also lacks the ability to enhance autophagy,
whereas these defects are not observedwith another PINK1mutant
with impaired kinase activity [58]. Parkin, another protein that
is mutated in autosomal recessive forms of PD, appears to act
as a signal for selective autophagy of dysfunctional mitochondria
[59].
5. Role of autophagy in clearance of aggregate-prone
proteins—implications for therapeutic application
The two major routes for clearance of intracytoplasmic
aggregate-prone proteins are the ubiquitin–proteasome system
and the autophagy–lysosomal pathway. Whereas most large
aggregate-prone proteins are precluded from entering the narrow
pore of the proteasome barrel once they oligomerize, such pro-
teins can be cleared by autophagy. The aggregate-prone species of
such proteins (e.g., mutant huntingtin) are highly dependent on
autophagy for their clearance, in contrast to the wild-type species
[60,61]. Wild-type -synuclein clearance can also be enhanced by
autophagy upregulation [62].
6 ll & D
5
a
5
i
e
i
i
m
m
b
t
m
e
a
a
p
w
p

t
e
i
m
p
a
v
a
t
g
s
B
p
o
t
R
c
d
i
u
r
p
5
e
t
e
w
n
p
l
v
i
c
a
h
v
d
h
p
Acknowledgements96 M. García-Arencibia et al. / Seminars in Ce
.1. Possible candidates for pharmacological induction of
utophagy
.1.1. mTOR-dependent pathway
Chemical induction of autophagy protects cells against the toxic
nsults of aggregate-prone proteins associated with neurodegen-
ration by promoting their clearance. The very ﬁrst known drug
dentiﬁed as an autophagy inducer is rapamycin,whichwas already
n clinical use for other indications. Rapamycin is a lipophilic
acrolide antibiotic originally used as an immunosuppressant. In
ammalian cells, rapamycin inhibits the kinase activity of mTOR
y forming a complex with the immunophilin FK506-binding pro-
ein of 12kDa (FKBP12) [63,64]. Rapamycin acts speciﬁcally on the
TORC1 complex that suppresses autophagy when active.
Our studies have established that rapamycin treatment
nhances the clearance of mutant huntingtin fragments, reduces
ggregate formationandprotects against toxicity in cell,Drosophila
nd mouse models of HD [60,65,66]. We also show that rapamycin
romotes the clearanceof awide rangeof aggregate-proneproteins
ith polyglutamine- or polyalanine-expansion (including mutant
roteins associated with spinocerebellar ataxias, mutant forms of
-synuclein implicated in PD, and mutant tau responsible for FTD),
hereby attenuating their toxicity [62,67]. CCI-779, a rapamycin
ster (i.e., an analogue of rapamycin) reduces both mutant hunt-
ngtin and ataxin-3 levels, thereby attenuating toxicity in mouse
odels of HD and SCA3, respectively [68,69].
In Drosophila, the beneﬁcial effects of rapamycin against such
roteins are autophagy dependent—no improvement is seen when
utophagy is compromised [66,70,71]. These ﬁndings support the
iew that the primary beneﬁts of this drug are mediated by
utophagy and not by alternative mechanisms, like disruption of
he translational machinery. Recently, delivery of the Beclin 1
ene was shown to induce autophagy and reduce amyloid and -
ynuclein pathology in mouse models of AD and Parkinson/Lewy
ody diseases, respectively [56,57]. This provides proof of princi-
le for autophagy induction as a protective strategy in awide range
f neurodegenerative diseases.
In addition, autophagy induction confers additional cytoprotec-
ive effects by virtue of its apparent anti-apoptoticmechanism [72].
apamycin treatment and autophagy upregulation also protects
ells against subsequent pro-apoptotic insults that are indepen-
ent of aggregates (e.g., Bax overexpression and staurosporine
n cell culture and paraquat toxicity in Drosophila [72]). Hence,
pregulating autophagy has two distinct beneﬁcial effects in neu-
odegenerative diseases: it promotes clearance of aggregate-prone
roteins, as well as protecting cells against pro-apoptotic insults.
.1.2. mTOR-independent pathway
Although rapamycin is designed for long-term use, it has side
ffects which may make it unattractive to patients who may need
o take the drug for decades. As far as we are aware, these side
ffects are unrelated to its autophagy-inducing properties. Thus,
e and others have embarked on a series of studies to identify
ovel autophagy-upregulating compounds and have discovered
athways that are independent of the target of rapamycin. Inositol-
owering drugs, including mood-stabilizing drugs such as lithium,
alproate and carbamazepine, can induce autophagy by inhibiting
nositol monophosphatase (IMPase), leading to depletion of intra-
ellular inositol levels and inhibition of the phospho-inositol cycle,
s described above [23,73]. Indeed, such drugs enhance mutant
untingtin clearance and protect against its toxicity in cell and in
ivo models [23,24,74], and thus may be potential therapeutic can-
idates for neurodegenerative diseases via autophagic clearance.
Another compound, trehalose, inhibits aggregation of mutant
untingtin and reduces toxicity in cells, and alleviates disease
athology in an HD mouse model [75]. Trehalose is a non-reducingevelopmental Biology 21 (2010) 691–698
disaccharide found in various non-mammalian species that pro-
tects cells against many environmental stresses, as it functions as
a “chemical chaperone” that assists in protein-folding. We have
recently identiﬁed trehalose as a novel autophagy inducer which
promotes the clearance of aggregate-prone proteins like mutant
huntingtin, and -synuclein mutants (A30P and A53T) via an
mTOR-independent pathway [75]. Besides, it also confers protec-
tion against cell death. In view of the diverse protective effects of
trehalose in different models of proteinopathies, its prospect for
treatment of neurodegenerative diseases warrants further consid-
eration for development into clinical use.
5.2. Screening of compounds—SMERs and various drugs
To explore other novel therapeutic agents capable of modu-
lating autophagy for the purpose of treating neurodegeneration,
high-throughput chemical screens were performed and various
small molecule inhibitors (SMIRs) and enhancers (SMERs) of the
growth-suppressing properties of rapamycin in yeast were identi-
ﬁed [76]. Among these, three SMERs (SMERs 10, 18 and 28) were
subsequently conﬁrmed to induce mTOR-independent autophagy
in mammalian cells as they increased clearance of autophagy
substrates such as A53T -synuclein and mutant huntingtin and
reduced huntingtin toxicity in the Drosophila HD model [76].
In addition, further screening of a library of FDA-approved
drugs/compounds was carried out in order to search for alter-
native therapeutic candidates to rapamycin. This screen revealed
that L-type Ca2+ channel antagonists (e.g., verapamil, loperamide
and amiodarone), the K+ATP channel opener minoxidil and the Gi-
signalling activator clonidine [24] induced autophagy. These com-
pounds induce autophagy by acting on the cAMP–Epac–PLC–IP3
pathway, which modulates calpain activity by inﬂuencing Ca2+
levels, as described above. It is notable that the drugs acting
on this pathway enhance mutant huntingtin clearance via an
mTOR-independent autophagy pathway, decrease mutant hunt-
ingtin aggregate levels and confer protection against toxicity in HD
cell, ﬂy and zebraﬁsh models [24,77].
6. Future perspective
The prospect of upregulating autophagy as therapy for certain
neurodegenerative diseases (e.g., Huntington disease) nonetheless
raises some challenges. In principle, earlier treatment would be
desired to delay the onset of disease. As most patients will have
family history, it is possible to identify at-risk individuals by genetic
screening [78]. Although rapamycinhasbeen tailored for long-term
use [79], it still has side effects due to inhibition of mTOR, which
regulatesmany other cellular processes independent of autophagy.
One consideration is that this approach may not require contin-
uous autophagy upregulation. Indeed, the “pulsatile” induction of
autophagy with spaced rapamycin administration was the strategy
we employed in our mouse studies [72,80], and this may be appli-
cable in humans with possibly even longer gaps between doses.
However, other alternatives such mTOR-independent drugs or a
combination of mTOR-dependent and -independent therapy may
be more suitable for long-term use. As such, a detailed under-
standing of pathways regulating autophagy will be of paramount
importance in the context of neurodegenerative disease.We are grateful to the Wellcome Trust (Senior Fellowship
to DCR), MRC (Programme grant to DCR), the NIHR Biomedical
Research Centre at Addenbrooke’s Hospital and the Yousef Jameel
Scholarship (for PT) for funding work related to this review.
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